Natera (NASDAQ:NTRA) Given New $160.00 Price Target at Robert W. Baird

Natera (NASDAQ:NTRA) had its price target boosted by investment analysts at Robert W. Baird from $120.00 to $160.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s price target indicates a potential upside of 18.41% from the stock’s previous close.

A number of other research firms have also recently commented on NTRA. Piper Sandler reissued an “overweight” rating and set a $150.00 target price on shares of Natera in a research report on Friday, September 13th. StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Morgan Stanley boosted their target price on Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. TD Cowen upped their target price on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Stephens reissued an “overweight” rating and issued a $125.00 price target on shares of Natera in a report on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $128.19.

Natera Price Performance

NTRA opened at $135.12 on Wednesday. The firm has a market capitalization of $16.71 billion, a PE ratio of -55.15 and a beta of 1.53. The business’s 50-day moving average is $125.09 and its two-hundred day moving average is $114.52. Natera has a 1 year low of $46.96 and a 1 year high of $140.00. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01.

Insider Buying and Selling at Natera

In related news, insider Solomon Moshkevich sold 256 shares of the firm’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total value of $30,737.92. Following the completion of the sale, the insider now owns 111,891 shares in the company, valued at $13,434,752.37. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, insider Jonathan Sheena sold 12,000 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the sale, the insider now owns 287,441 shares in the company, valued at $34,783,235.41. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Solomon Moshkevich sold 256 shares of the company’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total transaction of $30,737.92. Following the transaction, the insider now directly owns 111,891 shares of the company’s stock, valued at $13,434,752.37. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 47,464 shares of company stock worth $5,849,977. 7.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Farallon Capital Management LLC increased its holdings in shares of Natera by 13.6% in the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock valued at $483,034,000 after acquiring an additional 532,874 shares during the last quarter. First Light Asset Management LLC raised its holdings in shares of Natera by 295.9% in the 1st quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock worth $60,063,000 after purchasing an additional 490,822 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Natera by 257.6% in the second quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company’s stock valued at $70,553,000 after buying an additional 469,327 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Natera by 53.6% during the second quarter. Marshall Wace LLP now owns 958,383 shares of the medical research company’s stock valued at $103,783,000 after purchasing an additional 334,630 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in Natera by 311.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 406,653 shares of the medical research company’s stock worth $44,036,000 after buying an additional 307,920 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.